These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 32657741)

  • 1. Development of a method to determine the cost of breast cancer treatment with chemotherapy at Groote Schuur Hospital, Cape Town, South Africa.
    Guzha NT; Thebe T; Butler N; Valodia PN
    S Afr Med J; 2020 Mar; 110(4):296-301. PubMed ID: 32657741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained reduction in antibiotic consumption in a South African public sector hospital; Four year outcomes from the Groote Schuur Hospital antibiotic stewardship program.
    Boyles TH; Naicker V; Rawoot N; Raubenheimer PJ; Eick B; Mendelson M
    S Afr Med J; 2017 Jan; 107(2):115-118. PubMed ID: 28220735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
    Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
    Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings.
    Houts AC; Olufade T; Shenolikar R; Walker MS; Schwartzberg LS
    Cancer Treat Res Commun; 2019; 19():100121. PubMed ID: 30785027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Febrile neutropaenia and chemotherapy discontinuation in women aged 70 years or older receiving adjuvant chemotherapy for early breast cancer.
    Adjogatse D; Thanopoulou E; Okines A; Thillai K; Tasker F; Johnston SR; Harper-Wynne C; Torrisi E; Ring A
    Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):692-6. PubMed ID: 24909701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the costs and resource use associated with adjuvant chemotherapy for breast cancer in France.
    Laas E; Vataire AL; Aballea S; Valentine W; Gligorov J; Chereau E; Rouzier R
    J Med Econ; 2012; 15(6):1167-75. PubMed ID: 22853442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse breast cancer treatment effects: the economic case for making rehabilitative programs standard of care.
    Schmitz KH; DiSipio T; Gordon LG; Hayes SC
    Support Care Cancer; 2015 Jun; 23(6):1807-17. PubMed ID: 25471182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost comparison of radiation treatment options after lumpectomy for breast cancer.
    Greenup RA; Camp MS; Taghian AG; Buckley J; Coopey SB; Gadd M; Hughes K; Specht M; Smith BL
    Ann Surg Oncol; 2012 Oct; 19(10):3275-81. PubMed ID: 22851048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determining the morphological features of breast cancer and predicting the effects of neoadjuvant chemotherapy via diagnostic breast imaging.
    Tsunoda-Shimizu H; Hayashi N; Hamaoka T; Kawasaki T; Tsugawa K; Yagata H; Kikuchi M; Suzuki K; Nakamura S
    Breast Cancer; 2008; 15(2):133-40. PubMed ID: 18288570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Study of S-1 Combined With Low-Dose Docetaxel as Neoadjuvant Chemotherapy for Operable Breast Cancer Patients (N-1 Study).
    Nakagawa M; Ikeuchi M; Morimoto M; Takechi H; Toba H; Yoshida T; Okumura K; Hino N; Nishisho A; Tangoku A
    Clin Breast Cancer; 2019 Feb; 19(1):10-16. PubMed ID: 30340871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic imaging in neoadjuvant chemotherapy of locally-advanced breast cancer should be cost-effective.
    Schegerin M; Tosteson AN; Kaufman PA; Paulsen KD; Pogue BW
    Breast Cancer Res Treat; 2009 Apr; 114(3):537-47. PubMed ID: 18437559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resource implications of palliative chemotherapy for ovarian cancer.
    Doyle C; Stockler M; Pintilie M; Panesar P; Warde P; Sturgeon J; Oza AM
    J Clin Oncol; 1997 Mar; 15(3):1000-7. PubMed ID: 9060539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and financial burdens of secondary level care in a public sector antiretroviral roll-out setting (G. F. Jooste Hospital).
    Kevany S; Meintjes G; Rebe K; Maartens G; Cleary S
    S Afr Med J; 2009 May; 99(5):320-5. PubMed ID: 19588792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The economic burden of metastatic breast cancer: a U.S. managed care perspective.
    Montero AJ; Eapen S; Gorin B; Adler P
    Breast Cancer Res Treat; 2012 Jul; 134(2):815-22. PubMed ID: 22684273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
    McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
    Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population.
    Kruse GB; Amonkar MM; Smith G; Skonieczny DC; Stavrakas S
    J Manag Care Pharm; 2008; 14(9):844-57. PubMed ID: 19006441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.
    Hurvitz S; Guerin A; Brammer M; Guardino E; Zhou ZY; Latremouille Viau D; Wu EQ; Lalla D
    Oncologist; 2014 Sep; 19(9):901-8. PubMed ID: 25085897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of axillary nodal imaging by magnetic resonance imaging based on breast cancer subtype after neoadjuvant chemotherapy.
    Steiman J; Soran A; McAuliffe P; Diego E; Bonaventura M; Johnson R; Ahrendt G; McGuire K
    J Surg Res; 2016 Jul; 204(1):237-41. PubMed ID: 27451892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant Systemic Therapy Use for Younger Patients with Breast Cancer Treated in Different Types of Cancer Centers Across the United States.
    Mohiuddin JJ; Deal AM; Carey LA; Lund JL; Baker BR; Zagar TM; Jones EL; Marks LB; Chen RC
    J Am Coll Surg; 2016 Nov; 223(5):717-728.e4. PubMed ID: 27788894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.